Aptevo Therapeutics (APVO) Stock Rockets On Second Remission

Aptevo Therapeutics APVO Stock News

Aptevo Therapeutics Inc (NASDAQ: APVO) is screaming for the top in the market this morning, trading on gains that are better stated in multiples than percentages. The gains come for good reason. After announcing its first complete remission in a Phase 1 clinical trial last week, the company announced that its second patient in the trial has achieved complete remission. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

APVO Stock Is Climbing On Second Complete Remission

Aptevo Therapeutics is currently working on a Phase 1 clinical trial surrounding its candidate, APVO436. Teh treatment is being developed as a potential option for patients with acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS), both of which are incredibly difficult to treat cancers.

Nonetheless, there may be a highly effective treatment on the horizon for this patient population. Last week, Aptevo Therapeutics announced that a patient in this Phase 1 clinical trial achieved complete remission, which is a promising and unexpected sign of efficacy. That sign of efficacy was further validated this morning when the company announced its second complete remission.

Importantly, this patient was also in cohort 6, a cohort that includes nine patients. So far in the cohort, two patients have achieved complete remission, one patient has achieved stable disease status, and six patients have experienced disase progression.

In terms of the second patient that achieved complete remission, when entering the clinical trial, the patient had bone marrow blasts at 33%. APVO explained that this figure rose to 46% after the first cycle of treatment. Following the second cycle, bone marrow blasts had fallen to 8%, and at the end of the fourth cycle of treatment, bone marrow blasts had fallen to 4%. Moreover, the patients platelet count and absolute neutrophil count met complete remission criteria.

In a statement, Marvin White, President and CEO at APVO, had the following to offer:

It is very encouraging that two complete remissions have been observed in Cohort 6, as we are now enrolling in cohort 8. We are now in a critical phase of the study, as pharmacokinetic modelling suggests that dosing in cohorts 5 through 8 is in a therapeutic range, which could result in potential clinical activity of the drug. We look forward to continuing the dose escalation and monitoring potential clinical responses as we advance through the upcoming dose cohorts.

This Is Huge News

The data in the Phase 1 clinical trial has proven to be overwhelmingly positive, and it seems as though the company may really be onto something with the parameters set in Cohort 6 of the study. While the data is still very early, two patients with incredibly difficult to treat cancers have already achieved remission.

When looking at the data from the other patients, you may be turned off, but the details of the second patient that reached remission show promise for all in the study. Keep in mind, the second patient to achieve complete remission realized disease progression after the first dose. However, all subsequent doses led to the steady elimination of disease.

So, while six patients in the cohort are experiencing disease progression, they may still experience positive results from the treatment.

Nonetheless, even if the trial were stopped now and the data stood as it is, with 2 of 9 patients achieving complete remission, that would be great news for the AML and MDS community. Ultimately, with few effective treatment options, APVO, and its APVO436 are a light at the end of the tunnel for this patient population.

All in all, with such compelling data, APVO stock is one to watch incredibly closely.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas

Don't Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.